Resolution of an online meeting of the Volga Federal District experts on the EMPEROR-Reduced trial “A new era in the treatment of patients with HF. From EMPA-REG OUTCOME to EMPEROR-Reduced trial”

Resolution of an online meeting of the Volga Federal District experts on the EMPEROR-Reduced trial “A new era in the treatment of patients with HF. From EMPA-REG OUTCOME to EMPEROR-Reduced trial”

An online meeting of experts held on November 6, 2020 describes the results of EMPA-REG OUTCOME and EMPEROR-Reduced trials on sodium-glucose co-transporter-2 (SGLT2) inhibitor empagliflozin. We analyzed cardiovascular and renal outcomes in patients with and without type 2 diabetes (T2D) receiving em...

Full description

Bibliographic Details
Main Authors: S. V. Villevalde, A. S. Galyavich, N. G. Vinogradova, E. N. Volodina, I. R. Gaisin, S. R. Gilyarevsky, L. V. Grekhova, Yu. A. Guryanova, P. S. Guseva, D. V. Duplyakov, A. V. Ezhov, N. E. Zakirova, Yu. V. Zolotova, A. V. Isakov, S. V. Kanysheva, Z. F. Kim, V. P. Kuzmin, S. S. Markiyanova, S. A. Pomosov, A. P. Rebrov, E. I. Tarlovskaya, S. N. Tolstov, I. V. Fomin, N. R. Khasanov, A. M. Shutov
Format: Article
Language:Russian
Published: «FIRMA «SILICEA» LLC  2021-07-01
Series:Российский кардиологический журнал
Subjects:
empagliflozin
heart failure
cardiovascular mortality
chronic kidney disease
emperor-reduced trial
empa-reg outcome trial
Online Access:https://russjcardiol.elpub.ru/jour/article/view/4562

Internet

https://russjcardiol.elpub.ru/jour/article/view/4562

Similar Items